markertherapeutics.com (MRKR): חובות להיוון בספרים

The development of patentable T-cell therapies for hematological malignancies builds long-term capital for Marker Therapeutics (MRKR). The company's total debt-to-equity ratio reflects the dynamics of these investments, with 0.00 recorded as the baseline value. The safe MultiTAA technology reduces therapy costs, while streamlined air delivery channels for reagents minimize operational risks, stabilizing financial performance.

This ratio compares total liabilities to the book value of equity, determining the business's degree of financial leverage. For Marker Therapeutics (MRKR), this balance is critical when financing costly cryogenic logistics for cell therapy. By analyzing the history of debt levels relative to capitalization, an investor assesses the stability of the financing structure. A decrease in this metric minimizes default risk, yet limits the potential return on equity.